Promising Biotech Stocks To Watch Now - June 7th

Thermo Fisher Scientific, AbbVie, Veeva Systems, Danaher, Vertex Pharmaceuticals, IQVIA, and Cencora are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use living organisms or their components to develop drugs, therapies and diagnostic tools. Their performance often hinges on clinical‐trial results, regulatory approvals and scientific breakthroughs, making them typically more volatile but with the potential for significant gains. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of NYSE TMO traded up $3.63 during trading on Friday, reaching $401.99. 2,629,538 shares of the company traded hands, compared to its average volume of 1,908,231. Thermo Fisher Scientific has a 12-month low of $390.50 and a 12-month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market cap of $151.75 billion, a P/E ratio of 24.32, a PEG ratio of 2.99 and a beta of 0.78. The firm's fifty day simple moving average is $420.74 and its 200 day simple moving average is $495.93.

Read Our Latest Research Report on TMO

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV traded up $2.42 during mid-day trading on Friday, reaching $189.89. The company had a trading volume of 3,604,574 shares, compared to its average volume of 6,231,290. AbbVie has a 52-week low of $163.52 and a 52-week high of $218.66. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The stock has a market capitalization of $335.42 billion, a P/E ratio of 79.12, a PEG ratio of 1.62 and a beta of 0.50. The stock has a 50 day moving average of $184.24 and a two-hundred day moving average of $186.96.

Read Our Latest Research Report on ABBV

Veeva Systems (VEEV)

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

VEEV stock traded down $4.86 during mid-day trading on Friday, reaching $285.08. 2,087,466 shares of the company's stock were exchanged, compared to its average volume of 1,135,960. The stock's 50 day moving average is $235.57 and its 200 day moving average is $230.08. Veeva Systems has a 12-month low of $176.41 and a 12-month high of $291.68. The company has a market cap of $46.38 billion, a price-to-earnings ratio of 70.39, a price-to-earnings-growth ratio of 1.89 and a beta of 0.99.

Read Our Latest Research Report on VEEV

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of Danaher stock traded up $3.98 during mid-day trading on Friday, reaching $196.13. 2,802,212 shares of the stock traded hands, compared to its average volume of 3,481,847. Danaher has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $140.36 billion, a PE ratio of 37.15, a PEG ratio of 2.66 and a beta of 0.77. The business has a 50-day moving average of $191.34 and a 200 day moving average of $212.34.

Read Our Latest Research Report on DHR

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

VRTX stock traded up $6.68 during midday trading on Friday, hitting $450.50. 960,469 shares of the company's stock were exchanged, compared to its average volume of 1,417,133. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The business has a 50-day simple moving average of $465.01 and a two-hundred day simple moving average of $460.27. The stock has a market capitalization of $115.69 billion, a PE ratio of -204.77, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.

Read Our Latest Research Report on VRTX

IQVIA (IQV)

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

NYSE:IQV traded up $4.70 during midday trading on Friday, reaching $152.07. The company had a trading volume of 2,749,903 shares, compared to its average volume of 1,598,774. The firm has a market capitalization of $26.31 billion, a price-to-earnings ratio of 20.28, a PEG ratio of 1.99 and a beta of 1.28. The stock's fifty day simple moving average is $147.69 and its 200-day simple moving average is $179.13. IQVIA has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

Read Our Latest Research Report on IQV

Cencora (COR)

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

NYSE:COR traded up $0.60 during midday trading on Friday, reaching $289.01. The company had a trading volume of 1,302,615 shares, compared to its average volume of 1,526,744. Cencora has a 12-month low of $218.65 and a 12-month high of $309.35. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm has a market capitalization of $56.02 billion, a price-to-earnings ratio of 41.11, a PEG ratio of 1.31 and a beta of 0.58. The stock's fifty day simple moving average is $286.29 and its 200-day simple moving average is $260.15.

Read Our Latest Research Report on COR

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.